InterCure Ltd. cash flow to debt ratio of 9.20% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

InterCure Ltd.'s free cash flow has increased -118.64% from $-71.30M last year to $13.29M, signaling increasing performance

InterCure Ltd.'s debt to equity ratio is 0.46, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

InterCure Ltd.'s debt has decreased relative to shareholder equity from 0.53 last year to 0.46 today, signaling strengthened financials

InterCure Ltd. has negative EBITDA, making leverage ratio unreliable

InterCure Ltd.'s interest coverage ratio is -7.44, which means that the company struggles to meet interest obligations, signaling financial risk.

InterCure Ltd.'s profit margin has increased (-31.42%) in the last year from -28.38% to -19.47%, signaling increasing performance

InterCure Ltd.'s short-term assets of $316.75M exceed its short-term liabilities of $214.37M

InterCure Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

InterCure Ltd.'s return on equity of -8.77%, is lower than 15.00%, indicating bad performance

InterCure Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

InterCure Ltd. had positive net income in only 2.00 out of 5 years, indicating unstable earnings

InterCure Ltd. has positive free cash flow, indicating the company generates cash after capital expenditures

InterCure Ltd. has a free cash flow yield of 22.36%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

InterCure Ltd.'s yearly earnings has increased -47.33% since last year from $-67.80M to $-35.71M, signaling increasing performance

InterCure Ltd.'s yearly revenue has increased 13.13% since last year from $238.84M to $270.20M, signaling increasing performance

ROIC -4.79% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

InterCure Ltd.'s 3-year revenue CAGR of -11.41% is negative, indicating declining revenue over the past 3 years

InterCure Ltd. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

InterCure Ltd. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

InterCure Ltd. has insufficient data to evaluate this check.

InterCure Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

InterCure Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

InterCure Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

InterCure Ltd. is undervalued relative to its fair value price of 2.90 based on Earnings Fair Value model

InterCure Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

InterCure Ltd. has a price-to-book ratio of 0.45x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

InterCure Ltd. has a price-to-sales ratio of 0.97x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue